Credit Suisse’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-20,900
| Closed | -$51K | – | 3999 |
|
|
2021
Q4 | $51K | Buy |
+20,900
| New | +$48.9K | ﹤0.01% | 4420 |
|
|
2021
Q1 | – | Sell |
-15,000
| Closed | -$26K | – | 4449 |
|
|
2020
Q4 | $26K | Buy |
+15,000
| New | +$21K | ﹤0.01% | 4295 |
|
|
2019
Q4 | – | Sell |
-27,342
| Closed | -$27K | – | 4260 |
|
|
2019
Q3 | $27K | Buy |
27,342
+3,759
| +16% | +$3.89K | ﹤0.01% | 4076 |
|
|
2019
Q2 | $26K | Sell |
23,583
-4,202
| -15% | -$4.84K | ﹤0.01% | 4039 |
|
|
2019
Q1 | $36K | Buy |
27,785
+12,334
| +80% | +$15.3K | ﹤0.01% | 3921 |
|
|
2018
Q4 | $15K | Buy |
+15,451
| New | +$23.7K | ﹤0.01% | 3841 |
|
|
2018
Q3 | – | Sell |
-34,272
| Closed | -$62K | – | 3895 |
|
|
2018
Q2 | $62K | Sell |
34,272
-12,508
| -27% | -$25.2K | ﹤0.01% | 3882 |
|
|
2018
Q1 | $110K | Buy |
46,780
+7,779
| +20% | +$18.2K | ﹤0.01% | 3790 |
|
|
2017
Q4 | $73K | Sell |
39,001
-26,246
| -40% | -$57.3K | ﹤0.01% | 3879 |
|
|
2017
Q3 | $162K | Buy |
65,247
+42,030
| +181% | +$104K | ﹤0.01% | 3988 |
|
|
2017
Q2 | $64K | Sell |
23,217
-920
| -4% | -$2.57K | ﹤0.01% | 3761 |
|
|
2017
Q1 | $73K | Sell |
24,137
-18,424
| -43% | -$52.3K | ﹤0.01% | 3715 |
|
|
2016
Q4 | $134K | Buy |
42,561
+1,647
| +4% | +$5.06K | ﹤0.01% | 3902 |
|
|
2016
Q3 | $139K | Sell |
40,914
-8,109
| -17% | -$22.4K | ﹤0.01% | 3878 |
|
|
2016
Q2 | $112K | Buy |
+49,023
| New | +$120K | ﹤0.01% | 4035 |
|
|
2016
Q1 | – | Sell |
-16,459
| Closed | -$54K | – | 4159 |
|
|
2015
Q4 | $54K | Sell |
16,459
-1,496
| -8% | -$4.47K | ﹤0.01% | 4131 |
|
|
2015
Q3 | $43K | Sell |
17,955
-2,619
| -13% | -$6.78K | ﹤0.01% | 4190 |
|
|
2015
Q2 | $60K | Buy |
+20,574
| New | +$79.8K | ﹤0.01% | 4447 |
|
|
2015
Q1 | – | Sell |
-13,134
| Closed | -$40K | – | 4482 |
|
|
2014
Q4 | $40K | Sell |
13,134
-1,759
| -12% | -$4.76K | ﹤0.01% | 4530 |
|
|
2014
Q3 | $37K | Sell |
14,893
-4,206
| -22% | -$10.1K | ﹤0.01% | 4368 |
|
|
2014
Q2 | $47K | Sell |
19,099
-79,757
| -81% | -$180K | ﹤0.01% | 4594 |
|
|
2014
Q1 | $263K | Buy |
98,856
+4,716
| +5% | +$13.9K | ﹤0.01% | 4184 |
|
|
2013
Q4 | $274K | Buy |
94,140
+64,147
| +214% | +$194K | ﹤0.01% | 4136 |
|
|
2013
Q3 | $92K | Buy |
29,993
+13,976
| +87% | +$44.2K | ﹤0.01% | 4118 |
|
|
2013
Q2 | $51K | Buy |
+16,017
| New | +$51.3K | ﹤0.01% | 4095 |
|
Other funds holding LCTX
BC
DC
PGP
RA
Credit Suisse's LCTX Position: Q1 2022 in Review
Credit Suisse sold out of Lineage Cell Therapeutics (LCTX) in Q1 2022, closing a stake of 20,900 shares — an estimated $51K sold.
Credit Suisse first reported a position in LCTX in Q2 2013 and held it in 25 quarters. The position peaked at $274K in Q4 2013. 110 funds tracked by Wall St. Rank hold LCTX as of Q1 2022.
- Credit Suisse reported no remaining Lineage Cell Therapeutics position as of Q1 2022 after selling out during the quarter.
- Credit Suisse sold 20,900 Lineage Cell Therapeutics shares in Q1 2022, an estimated $51K.
- Credit Suisse first reported a position in Lineage Cell Therapeutics in Q2 2013 and held it in 25 quarters.
- Credit Suisse's Lineage Cell Therapeutics position peaked at $274K in Q4 2013.
- 110 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2022.
Based on Credit Suisse's 13F filing for Q1 2022, filed 16 May 2022.